Methods and compositions for transforming dendritic cells and activating cells
AssigneesGovernment of the United States of America, Represented By the Secretary, Dept., of Health and Human Services Office of Technology Transfer
InventorsPatrick Hwu, Mark Reeves, Steven A. Rosenberg
Life of this patent
Estimating the term…
Abstract
Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen presenting cell which activates T cells against MHC class I-antigen targets. Kits, assays and therapeutics are based upon the activation of T cells by the recombinant dendritic cell. Cancer, viral infections and parasitic infections are all ameliorated by the recombinant dendritic cells, or corresponding activated T cells. Therapeutic compositions and pharmaceutical compositions are provided.
Claims6
1-38. (canceled)
A method of killing a target cell, comprising:
- transforming a hematopoietic stem cell in vitro with a recombinant expression cassette comprising a nucleic acid encoding an antigenic peptide, and differentiating the transformed stem cell into a transformed dendritic cell;
- contacting a T cell with the transformed dendritic cell, thereby providing an activated T cell, wherein the T cell and the hematopoietic stem cell are from the same individual;
- and
- contacting the target cell with the activated T cell, wherein the target cell expresses a protein comprising the antigenic peptide.
43-49. (canceled)
Dependencies are inferred from the claim text.